


BEVACIZUMAB (or biosimilar)

Indication	<ul style="list-style-type: none"> • Acute aggressive ROP¹⁻³ • Type 1 ROP^{1,3} in posterior zone 2 <ul style="list-style-type: none"> ○ Any stage in zone 1, 2 or 3 with plus disease, or ○ Stage 3 in zone 1 without plus disease³ • If unsuitable for ROP laser treatment³, due to <ul style="list-style-type: none"> ○ Previous unsuccessful laser attempt³ ○ Inability to tolerate procedure³ ○ Poor view of retina³ 		
OPHTHALMIC	Presentation	• Prefilled syringe: 3 mg in 0.12 mL	
	Dosage ^{1,2,4,5}	• Single dose: 0.313 mg or 0.625 mg	
	Preparation	• Nil required	
	Administration	<ul style="list-style-type: none"> • Intravitreal injection (under sterile conditions) <ul style="list-style-type: none"> ○ Performed by ophthalmologist or ophthalmology fellow ONLY 	
Special considerations	<ul style="list-style-type: none"> • Complete treatment within 24–48 hours of identifying ROP and indication for treatment³ • Injection may be repeated at ophthalmologist discretion • Prior to administration, provide pain relief (e.g. paracetamol) • Consider procedural sedation (e.g. intranasal dexmedetomidine) • During administration, provide supportive measures (e.g. swaddling, oral sucrose) • Post administration, dim room lights as pupils can remain dilated for up to 4 hours • If bilateral administration, different batch number per single eye injection recommended 		
Monitoring	<ul style="list-style-type: none"> • Red reflex check, day after injection <ul style="list-style-type: none"> ○ Performed by clinician skilled in assessing red reflex 		
Compatibility	• Not applicable		
Incompatibility	• Not applicable		
Interactions	• Nil known		
Stability ⁶	• Refrigerate 2–8°C		
Side effects	<ul style="list-style-type: none"> • Ocular: ocular inflammation^{2,6}, ocular infection⁶, ocular haemorrhage⁷, retinal detachment^{2,4,8}, cataract⁷, loss of vision (rare)⁸ • Respiratory: apnoea⁶ 		
Actions	<ul style="list-style-type: none"> • Anti-VEGF monoclonal antibody^{2,4,8} <ul style="list-style-type: none"> ○ Blocks VEGF formation and inhibits formation of new blood vessels^{1,2,4,9} 		
Abbreviations	Anti-VEGF: anti-vascular endothelial growth factor, ROP: retinopathy of prematurity, VEGF: vascular endothelial growth factor		
Keywords	anti-VEGF, antivascular endothelial growth factor, avastin, bevacizumab, mvasi, neonatal medicine, neonatal monograph, ROP, retinopathy of prematurity, VEGF		

The Queensland Clinical Guideline *Neonatal Medicines* is integral to and should be read in conjunction with this monograph. Refer to the disclaimer. Destroy all printed copies of this monograph after use.

References

1. IBM Micromedex®/Neofax®. Bevacizumab. [Internet]. Colorado USA: Truven Health Analytics; 2024 [cited 2024 March 11]. Available from: <https://www.micromedexsolutions.com/neofax>.
2. Mintz-Hittner H, Kennedy K, Chuang A. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. *The New England Journal of Medicine* 2011;364(7):603-15. doi:10.1056/NEJMoa1007374.
3. RANZCO. Retinopathy of Prematurity (ROP) Screening and Treatment Guidelines. 2021.
4. Mueller B, Salchow D, Waffenschmidt E, Jousseaume A, Schmalisch G, Czernik C, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. *British Journal of Ophthalmology* 2017;101(3):365-70. doi:10.1136/bjophthalmol-2016-308375.
5. Liu C, Hong Z, Dai S, Sheth S, Shah S. Bevacizumab biosimilar (bevacizumab-awwb) is safe in the treatment of retinopathy of prematurity. *Clinical and Experimental Ophthalmology* 2024. doi:10.1111/ceo.14439.
6. Australian Injectable Drugs Handbook. Bevacizumab. [Internet]. New South Wales: Society of Hospital Pharmacists of Australia (SHPA); February 2024 [cited 2024 March 11]. Available from: <https://www.aidh.hcn.com.au>.
7. Sankar M, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. *Cochrane Database of Systematic Reviews*. [Internet]. 2018, [cited 2024 September 23]. Issue 1. Art No.: CD009734. DOI:10.1002/14651858.CD009734.pub3.
8. Chow SC, Lam PY, Lam WC, Fung NSK. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review. *Eye* 2022;36(8):1532-45. doi:10.1038/s41433-021-01922-2.
9. Australian Medicines Handbook. Bevacizumab. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2024 [cited 2024 March 11]. Available from: <https://www.amhonline.amh.net.au>.

Document history

ID number	Effective	Review	Summary of updates
NMedQ24.118-V1-R29	05/11/24	05/11/29	Endorsed by Queensland Neonatal Services Advisory Group (QNSAG)

QR code

